{
    "Clinical Trial ID": "NCT00723125",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cohort 1",
        "  Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "  Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)",
        "INTERVENTION 2: ",
        "  Cohort 2",
        "  Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks",
        "  Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)"
    ],
    "Eligibility": [
        "Eligibility criteria",
        "Inclusion criteria:",
        "  Histologically documented adenocarcinoma of the breast",
        "  ANC > 1000 cells",
        "  Female; age > 18",
        "  Zubrod PS 0-1",
        "  Platelets > 100,000",
        "  Stage IIA-IIIB disease",
        "  Total bilirubin < 1.5 ULN",
        "  No evidence of any metastatic disease",
        "  Serum Creatinine < 1.5 gm/dl",
        "  No prior systemic therapy for breast cancer or Creat Cl > 30 ml/min",
        "  Not pregnant or lactating",
        "  Serum ALT < 2.0 ULN",
        "  ER, PR and HER2 status required",
        "  LVEF (MUGA/echo WNL)",
        "  No baseline > 2 neuropathy",
        "  Urine protein: creat ratio < 1.0",
        "  HER2-negative - either IHC 0-1+ or FISH ratio < 2.0",
        "  Hemoglobin > 9 gm/dl",
        "  (FISH testing is required for all HER2 2-3+ tumors by IHC)",
        "Exclusion criteria:",
        "  No Histologically documented adenocarcinoma of the breast",
        "  No-ANC > 1000 cells",
        "  Female; age < 18",
        "  Zubrod PS > 0-1",
        "  Platelets < 100,000",
        "  Stage IV disease",
        "  Total bilirubin > 1.5 ULN",
        "  metastatic disease",
        "  Serum Creatinine > 1.5 gm/dl",
        "  prior systemic therapy for breast cancer or Creat Cl > 30 ml/min",
        "  pregnant or lactating",
        "  Serum ALT > 2.0 ULN baseline > 2 neuropathy",
        "  Urine protein: creat ratio >1.0",
        "  HER2-positive",
        "  Hemoglobin < 9 gm/dl"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Pathological Complete Response Rates at Surgery",
        "  [Not Specified]",
        "  Time frame: at surgery approximately 5 months after initial treatment",
        "Results 1: ",
        "  Arm/Group Title: Cohort 1",
        "  Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "  Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: participants  16",
        "Results 2: ",
        "  Arm/Group Title: Cohort 2",
        "  Arm/Group Description: Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks",
        "  Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)",
        "  Overall Number of Participants Analyzed: 27",
        "  Measure Type: Number",
        "  Unit of Measure: participants  2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/28 (17.86%)",
        "  gr 3 Nausea, gr 3 vomiting  1/28 (3.57%)",
        "  gr 3 nausea, gr 2 infection with noraml ANC, gr 2 HGB, gr 1 glucose  1/28 (3.57%)",
        "  gr 2 non-cardiac chest pain, gr 2 anemia  1/28 (3.57%)",
        "  gr 3 infection (normal ANC) (cellulitis & pain in buttock - RT infection), gr 1 epistaxis  1/28 (3.57%)",
        "Adverse Events 2:",
        "  Total: 8/27 (29.63%)",
        "  gr 3 Nausea, gr 3 vomiting  0/27 (0.00%)",
        "  gr 3 nausea, gr 2 infection with noraml ANC, gr 2 HGB, gr 1 glucose  0/27 (0.00%)",
        "  gr 2 non-cardiac chest pain, gr 2 anemia  0/27 (0.00%)",
        "  gr 3 infection (normal ANC) (cellulitis & pain in buttock - RT infection), gr 1 epistaxis  0/27 (0.00%)"
    ]
}